Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Pablo Jiménez-Labaig, Antonio Rullan, Irene Braña, Alberto Hernando-Calvo, Victor Moreno, Bernard Doger, George Bitar, Derfel Ap Dafydd, Alan Melcher, Kevin J Harrington
BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) presents an ideal scenario for intratumoral therapies (IT), due to its local recurrence pattern and frequent superficial extension. IT therapies aim to effect tumor regression by directly injecting antineoplastic agents into lesions. However, there is a lack of updated evidence regarding IT therapies in HNSCC. PATIENTS AND METHODS: A systematic literature search (CRD42023462291) was conducted using WebOfScience, ClinicalTrials...
April 27, 2024: Cancer Treatment Reviews
#2
REVIEW
Konstantinos Drougkas, Konstantinos Karampinos, Ioannis Karavolias, Georgia Gomatou, Ioannis-Alexios Koumprentziotis, Ioanna Ploumaki, Efthymios Triantafyllou, Elias Kotteas
BACKGROUND: Pancreatic and biliary tract cancers are digestive system tumors with dismal prognosis and limited treatment options. The effectiveness of conventional surgical interventions, radiation therapy, and systemic therapy is restricted in these cases. Furthermore, clinical trials have shown that immunotherapy using immune checkpoint inhibitors has only demonstrated modest clinical results when applied to patients with pancreatobiliary tumors. This highlights the importance of implementing combination immunotherapy approaches or exploring alternative therapeutic strategies to improve treatment outcomes...
May 2, 2024: Journal of Gastrointestinal Cancer
#3
JOURNAL ARTICLE
Douglas E Peterson, Shlomo A Koyfman, Noam Yarom, Charlotte Duch Lynggaard, Nofisat Ismaila, Lone E Forner, Clifton David Fuller, Yvonne M Mowery, Barbara A Murphy, Erin Watson, David H Yang, Ivan Alajbeg, Paolo Bossi, Michael Fritz, Neal D Futran, Daphna Y Gelblum, Edward King, Salvatore Ruggiero, Derek K Smith, Alessandro Villa, Jonn S Wu, Deborah Saunders
PURPOSE: To provide evidence-based recommendations for prevention and management of osteoradionecrosis (ORN) of the jaw secondary to head and neck radiation therapy in patients with cancer. METHODS: The International Society of Oral Oncology-Multinational Association for Supportive Care in Cancer (ISOO-MASCC) and ASCO convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. PubMed, EMBASE, and Cochrane Library databases were searched for randomized controlled trials and observational studies, published between January 1, 2009, and December 1, 2023...
May 1, 2024: Journal of Clinical Oncology
#4
JOURNAL ARTICLE
Deborah Saunders, Shlomo A Koyfman, Nofisat Ismaila, Neal D Futran, Yvonne M Mowery, Erin Watson, David H Yang, Douglas E Peterson
No abstract text is available yet for this article.
May 1, 2024: JCO oncology practice
#5
JOURNAL ARTICLE
Nicolas H Hart, Larissa Nekhlyudov, Thomas J Smith, Jasmine Yee, Margaret I Fitch, Gregory B Crawford, Bogda Koczwara, Fredrick D Ashbury, Maryam B Lustberg, Michelle Mollica, Andrea L Smith, Michael Jefford, Fumiko Chino, Robin Zon, Meera R Agar, Raymond J Chan
PURPOSE: People with advanced or metastatic cancer and their caregivers may have different care goals and face unique challenges compared with those with early-stage disease or those nearing the end of life. These Multinational Association for Supportive Care in Cancer (MASCC)-ASCO standards and practice recommendations seek to establish consistent provision of quality survivorship care for people affected by advanced or metastatic cancer. METHODS: A MASCC-ASCO expert panel was formed...
April 29, 2024: JCO oncology practice
#6
JOURNAL ARTICLE
Hedyeh Ebrahimi, Sandra Megally, Elana Plotkin, Latha Shivakumar, Nicholas J Salgia, Zeynep B Zengin, Luis Meza, Neal Chawla, Daniella V Castro, Nazli Dizman, Ruma Bhagat, Seila Liv, Xiaochen Li, Adam Rock, Sandy Liu, Abhishek Tripathi, Tanya Dorff, Randall A Oyer, Leigh Boehmer, Sumanta Pal, Alexander Chehrazi-Raffle
IMPORTANCE: While an overwhelming majority of patients diagnosed with cancer express willingness to participate in clinical trials, only a fraction will enroll onto a research protocol. OBJECTIVE: To identify critical barriers to trial enrollment to translate findings into actionable practice changes that increase cancer clinical trial enrollment. DESIGN, SETTING, AND PARTICIPANTS: This survey study included designated site contacts at oncology practices with teams who were highly involved with the Association of Community Cancer Centers (ACCC) Community Oncology Research Institute (ACORI) clinical trials activities, all American Society of Clinical Oncology (ASCO)-ACCC collaboration pilot sites, and/or sites providing care to at least 25% African American and Hispanic residents...
April 1, 2024: JAMA Network Open
#7
JOURNAL ARTICLE
Nicolas H Hart, Larissa Nekhlyudov, Thomas J Smith, Jasmine Yee, Margaret I Fitch, Gregory B Crawford, Bogda Koczwara, Fredrick D Ashbury, Maryam B Lustberg, Michelle Mollica, Andrea L Smith, Michael Jefford, Fumiko Chino, Robin Zon, Meera R Agar, Raymond J Chan
PURPOSE: People with advanced or metastatic cancer and their caregivers may have different care goals and face unique challenges compared to those with early-stage disease or those nearing the end-of-life. These MASCC-ASCO standards and practice recommendations seek to establish consistent provision of quality survivorship care for people affected by advanced or metastatic cancer. METHODS: An expert panel comprising MASCC and ASCO members was formed. Standards and recommendations relevant to the provision of quality survivorship care for people affected by advanced or metastatic cancer were developed through conducting: (1) a systematic review of unmet supportive care needs; (2) a scoping review of cancer survivorship, supportive care, and palliative care frameworks and guidelines; and (3) an international modified Delphi consensus process...
April 29, 2024: Supportive Care in Cancer
#8
JOURNAL ARTICLE
Michal G Rose, Erin B Kennedy, Ghassan K Abou-Alfa, Richard S Finn, Terence Gade, R Kate Kelley, Tamar Taddei, John D Gordan
No abstract text is available yet for this article.
April 25, 2024: JCO oncology practice
#9
JOURNAL ARTICLE
Jeffrey Holzbeierlein, Brooke R Bixler, David I Buckley, Sam S Chang, Rebecca S Holmes, Andrew C James, Erin Kirkby, James M McKiernan, Anne Schuckman
PURPOSE: Although representing approximately 25% of patients diagnosed with bladder cancer, muscle-invasive bladder cancer (MIBC) carries a significant risk of death that has not significantly changed in decades. Increasingly, clinicians and patients recognize the importance of multidisciplinary collaborative efforts that take into account survival and quality of life concerns. This guideline provides a risk-stratified, clinical framework for the management of muscle-invasive urothelial bladder cancer...
April 25, 2024: Journal of Urology
#10
Amy C Moreno, Erin E Watson, Laia Humbert-Vidan, Douglas E Peterson, Lisanne V van Dijk, Teresa Guerrero Urbano, Lisa Van den Bosch, Andrew J Hope, Matthew S Katz, Frank J P Hoebers, Ruth A Aponte Wesson, James E Bates, Paolo Bossi, Adeyinka F Dayo, Mélanie Doré, Eduardo Rodrigues Fregnani, Thomas J Galloway, Daphna Y Gelblum, Issa A Hanna, Christina E Henson, Sudarat Kiat-Amnuay, Anke Korfage, Nancy Y Lee, Carol M Lewis, Charlotte Duch Lynggaard, Antti A Mäkitie, Marco Magalhaes, Yvonne M Mowery, Carles Muñoz-Montplet, Jeffrey N Myers, Ester Orlandi, Jaymit Patel, Jillian M Rigert, Deborah Saunders, Jonathan D Schoenfeld, Ugur Selek, Efsun Somay, Vinita Takiar, Juliette Thariat, Gerda M Verduijn, Alessandro Villa, Nick West, Max J H Witjes, Alex Won, Mark E Wong, Christopher M K L Yao, Simon W Young, Kamal Al-Eryani, Carly E A Barbon, Doke J M Buurman, François J Dieleman, Theresa M Hofstede, Abdul Ahad Khan, Adegbenga O Otun, John C Robinson, Lauren Hum, Jorgen Johansen, Rajesh Lalla, Alexander Lin, Vinod Patel, Richard J Shaw, Mark S Chambers, Daniel Ma, Mabi Singh, Noam Yarom, Abdallah Sherif Radwan Mohamed, Katherine A Hutcheson, Stephen Y Lai, Clifton David Fuller
PURPOSE: Osteoradionecrosis of the jaw (ORNJ) is a severe iatrogenic disease characterized by bone death after radiation therapy (RT) to the head and neck. With over 9 published definitions and at least 16 diagnostic/staging systems, the true incidence and severity of ORNJ are obscured by lack of a standard for disease definition and severity assessment, leading to inaccurate estimation of incidence, reporting ambiguity, and likely under-diagnosis worldwide. This study aimed to achieve consensus on an explicit definition and phenotype of ORNJ and related precursor states through data standardization to facilitate effective diagnosis, monitoring, and multidisciplinary management of ORNJ...
April 9, 2024: medRxiv
#11
JOURNAL ARTICLE
Amani Kais, Stell Patadji Santiago, Peng Cheng Han, David A Clump, William A Stokes, Tanya Fancy, Ruifeng Cui, Elizabeth Martin, Meghan T Turner
INTRODUCTION: Neck mass is the most common presentation of human papillomavirus-related (HPV-related) oropharyngeal squamous cell carcinoma (OPSCC). Recently, circulating tumor HPV-DNA (ctHPVDNA) assays have been developed to detect active OPSCC. This pilot study investigates the diagnostic accuracy of ctHPVDNA in establishing HPV status for known vs. unknown OPSCC presenting as a neck mass. METHODS: A single-institution pilot study was conducted on all patients with OPSCC presenting as a neck mass between 2021 and 2022...
2024: Frontiers in Oncology
#12
JOURNAL ARTICLE
M Polack, M A Smit, G W van Pelt, A G H Roodvoets, E Meershoek-Klein Kranenbarg, H Putter, H Gelderblom, A S L P Crobach, V Terpstra, G Petrushevska, G Gašljević, S Kjær-Frifeldt, E M V de Cuba, N W J Bulkmans, G R Vink, R Al Dieri, R A E M Tollenaar, J H J M van Krieken, W E Mesker
BACKGROUND: The TNM (tumor-node-metastasis) Evaluation Committee of Union for International Cancer Control (UICC) and College of American Pathologists (CAP) recommended to prospectively validate the cost-effective and robust tumor-stroma ratio (TSR) as an independent prognostic parameter, since high intratumor stromal percentages have previously predicted poor patient-related outcomes. PATIENTS AND METHODS: The 'Uniform Noting for International application of Tumor-stroma ratio as Easy Diagnostic tool' (UNITED) study enrolled patients in 27 participating centers in 12 countries worldwide...
April 12, 2024: ESMO Open
#13
JOURNAL ARTICLE
Maria T Bourlon, Ami S Bhatt, Gilberto Lopes, Fredrick Chite Asirwa, Alexandru E Eniu, Patrick J Loehrer, Lawrence N Shulman, Julia Close, Jamie Von Roenn, Michal Tibbits, Doug Pyle, Julie R Gralow
Recognizing the rising incidence, prevalence, and mortality of cancer in low- and middle-resource settings, as well as the increasingly international profile of its membership, ASCO has committed to expanding its engagement at a global level. In 2017, the ASCO Academic Global Oncology Task Force sought to define the potential role for ASCO in supporting global oncology as an academic field. A set of recommendations to advance the status of global oncology as an academic discipline were created through a consensus-based process involving participation by a diverse group of global oncology and global health practitioners; these recommendations were then published...
April 2024: JCO global oncology
#14
JOURNAL ARTICLE
Roberta Caputo, Giuseppe Buono, Michela Piezzo, Claudia Martinelli, Daniela Cianniello, Alessandro Rizzo, Francesco Pantano, Nicoletta Staropoli, Rodolfo Cangiano, Salvatore Turano, Ida Paris, Francesco Nuzzo, Alessandra Fabi, Michelino De Laurentiis
OBJECTIVE: The objective of this multicenter, observational, retrospective analysis was to evaluate the safety and efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer (mTNBC) patients managed according to common clinical practice in Italy. METHODS: Data were retrieved by 7 sites. Triple-negative BC was defined by the lack of expression of estrogen receptor (ER <1%), progesterone receptor (PgR <1%) and human-epidermal growth factor receptor-2 (HER2 0, 1+, 2+ ISH-not amplified) according to standard ASCO-CAP criteria...
2024: Frontiers in Oncology
#15
REVIEW
Samantha K F Kennedy, Shannon Goodall, Shing Fung Lee, Carlo DeAngelis, Allison Jocko, Flay Charbonneau, Katie Wang, Mark Pasetka, Yoo-Joung Ko, Henry C Y Wong, Adrian Wai Chan, Thenugaa Rajeswaran, Milena Gojsevic, Edward Chow, Richard J Gralla, Terry L Ng, Katarzyna J Jerzak
Chemotherapy-induced nausea and vomiting (CINV) is a common toxicity that may impair the quality of life of patients with various malignancies ranging from early to end stages. In light of frequent changes to the guidelines for optimal management of CINV, we undertook this narrative review to compare the most recent guidelines published by ASCO (2020), NCCN (2023), MASCC/ESMO (2023), and CCO (2019). The processes undertaken by each organization to evaluate existing literature were also described. Although ASCO, NCCN, MASCC/ESMO, and CCO guidelines for the treatment and prevention of CINV share many fundamental similarities, the literature surrounding low and minimal emetic risk regimens is lacking...
April 10, 2024: Supportive Care in Cancer
#16
JOURNAL ARTICLE
Susan Prendeville, Harpreet Kaur, Shervin Ansari, Shifaa Alqaqa, Tracy L Stockley, Katherine Lajkosz, Theodorus van der Kwast, Carol C Cheung, Shamini Selvarajah
Somatic tumor testing in prostate cancer (PCa) can guide treatment options by identifying clinically actionable variants in DNA damage repair (DDR) genes, including acquired variants not detected by germline testing alone. Guidelines currently recommend performing somatic tumor testing in metastatic PCa, while there is no consensus on the role of testing in regional disease and the optimal testing strategy is involving. This study evaluates the frequency, distribution, and pathologic correlates of somatic DDR mutations in metastatic and localized PCa following the implementation of pathologist-driven reflex testing at diagnosis...
April 6, 2024: Modern Pathology
#17
JOURNAL ARTICLE
Dwight H Owen, Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, Narjust Florez, Sonum Puri, Erin L Schenk, Bryan J Schneider, Jyoti D Patel
No abstract text is available yet for this article.
April 8, 2024: JCO oncology practice
#18
JOURNAL ARTICLE
Ushna Zameer, Wajiha Shaikh, Abdul Moiz Khan
Lung cancer imposes a burden on the health care system worldwide affecting 2 million people and causing 1.8 million deaths in 2021.More than 85% of all lung cancer cases are reported under Non-small-cell lung cancer (NSCLC). It is critical to discover gene alterations to treat non-small cell lung cancer successfully. The CAP/IASLC/AMP recommendations supported use of polymerase chain reaction (PCR) and fluorescent in situ hybridization (FISH) EGFR (epidermal growth factor receptor) mutations and ALK (Anaplastic lymphoma kinase) rearrangements, respectively...
2024: Cancer Informatics
#19
REVIEW
Jacqueline K Perez, Jeanene Kleber, Michael Rothe, Pam Mangat, Elizabeth Garrett-Mayer, Richard L Schilsky
PURPOSE: With the advent of precision medicine, molecular tumor boards (MTBs) were established to interpret genomic results and guide decision making for targeted therapy in oncology patients. There are currently no universal guidelines for how MTBs should operate and thus variance can be seen depending on which MTB is reviewing the case. This study assesses the concordance of MTB recommendations when a participant case is reviewed by two different MTBs, establishes potential reasons for discordance, and advocates for the establishment of standard MTB operating guidelines...
March 2024: JCO Precision Oncology
#20
REVIEW
Céleste Van Der Schueren, Philippe Decruyenaere, Francisco Avila Cobos, Johanna Bult, Jill Deleu, Laudonia Lidia Dipalo, Hetty Hilde Helsmoortel, Eva Hulstaert, Annelien Morlion, Elena Ramos Varas, Kathleen Schoofs, Wim Trypsteen, Eveline Vanden Eynde, Hanne Van Droogenbroeck, Kimberly Verniers, Jo Vandesompele, Anneleen Decock
Extracellular RNA (cell-free RNA; exRNA) from blood-derived liquid biopsies is an appealing, minimally invasive source of disease biomarkers. As pre-analytical variables strongly influence exRNA measurements, their reporting is essential for meaningful interpretation and replication of results. The aim of this review was to chart to what extent pre-analytical variables are documented, to pinpoint shortcomings and to improve future reporting. In total, 200 blood plasma exRNA studies published in 2018 or 2023 were reviewed for annotation of 22 variables associated with blood collection, plasma preparation, and RNA purification...
April 2, 2024: Molecular Oncology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
